The potential role of protein kinase R as a regulator of age-related neurodegeneration
Author
dc.contributor.author
Martínez, Nicolás W.
Author
dc.contributor.author
Gómez, Felipe E.
Author
dc.contributor.author
Matus, Soledad
Admission date
dc.date.accessioned
2021-11-29T21:51:49Z
Available date
dc.date.available
2021-11-29T21:51:49Z
Publication date
dc.date.issued
2021
Cita de ítem
dc.identifier.citation
Frontiers in Aging Neuroscience April 2021 Volume 13 Article 638208
es_ES
Identifier
dc.identifier.other
10.3389/fnagi.2021.638208
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/182935
Abstract
dc.description.abstract
There is a growing evidence describing a decline in adaptive homeostasis in agingrelated
diseases affecting the central nervous system (CNS), many of which are
characterized by the appearance of non-native protein aggregates. One signaling
pathway that allows cell adaptation is the integrated stress response (ISR), which senses
stress stimuli through four kinases. ISR activation promotes translational arrest through
the phosphorylation of the eukaryotic translation initiation factor 2 alpha (eIF2a) and
the induction of a gene expression program to restore cellular homeostasis. However,
depending on the stimulus, ISR can also induce cell death. One of the ISR sensors
is the double-stranded RNA-dependent protein kinase [protein kinase R (PKR)], initially
described as a viral infection sensor, and now a growing evidence supports a role for
PKR on CNS physiology. PKR has been largely involved in the Alzheimer’s disease
(AD) pathological process. Here, we reviewed the antecedents supporting the role of
PKR on the efficiency of synaptic transmission and cognition. Then, we review PKR’s
contribution to AD and discuss the possible participation of PKR as a player in the
neurodegenerative process involved in aging-related pathologies affecting the CNS.
es_ES
Patrocinador
dc.description.sponsorship
Programa de Apoyo a Centros con Financiamiento Basal AFB-170004
ANID/FONDAP program 15150012
Takeda Pharmaceutical Company Ltd P09-015-F
Project FONDECYT/ANID 2020 3200932
es_ES
Lenguage
dc.language.iso
en
es_ES
Publisher
dc.publisher
Frontiers Media
es_ES
Type of license
dc.rights
Attribution-NonCommercial-NoDerivs 3.0 United States